Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. [PDF]
, 2019 PURPOSE: To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.
Bohlius, Julia +12 more
core +3 more sources
Extended dosing of darbepoetin alfa in peritoneal dialysis patients
BMC Nephrology, 2011 Background Anemia is common among peritoneal dialysis (PD) patients, and most patients require erythropoiesis-stimulating agents (ESA) to maintain their hemoglobin concentrations within current guideline recommendations. Darbepoetin alfa is an ESA with a
Bridges Ian +6 more
doaj +1 more source
C-Reactive protein and risk of ESRD: results from the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) [PDF]
, 2016 Background: To better understand a potential association of elevated C-reactive protein (CRP) level with progression of chronic kidney disease (CKD), we examined the relationship of CRP level with the development of end-stage renal disease (ESRD) in ...
Burdmann, Emmanuel A. +12 more
core +1 more source
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]
, 2014 Aim<p></p> To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure) trial, testing ...
Adel R. Rizkala +11 more
core +3 more sources
Український Журнал Нефрології та Діалізу, 2015 The article describes the ways to cost optimization of anemia treatment CKD - HD patients. Aims. dinical and economic analysis treatment of Anemia CKD VHD PTS with using long action Erythropoiesis Stimulating Agents (ESA). Methods.
M. Kolesnyk, N. Bezdetko, V. Novakivskyy
doaj +1 more source
Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study [PDF]
, 2016 Background Since 2007 biosimilars of erythropoiesis-stimulating agents (ESAs) are available on the Italian market. Very limited post-marketing data exist on the comparative effectiveness of biosimilar and originator ESAs.
Alibrandi, A. (Angela) +12 more
core +6 more sources
Correction of ischemic optic neuropathy in rats by carbamylated darbepoetin [PDF]
, 2018 The protective effects of carbamylated darbepoetin on the model of ischemic optic neuropathy in rats were revealed. To increase the effectiveness of pharmacological correction of experimental ischemic optic neuropathy in an experiment by using ...
Peresypkina, A. A.
core +2 more sources
Pharmacology of darbepoetin alfa [PDF]
Nephrology Dialysis Transplantation, 2007 The distinct molecular structure of darbepoetin alfa, in both its amino acid sequence and its carbohydrate content, results in a biologic profile with lower binding affinity, longer circulating half-life, and higher in vivo potency compared with the epoetins.
Iain C, Macdougall +2 more
openaire +2 more sources
Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care [PDF]
, 2012 Author can archive publisher's pdf. Free via Creative Commons: CC-BENCHTOBEDSIDE-2.0.
Nandra, KK, Patel, NSA, Thiemermann, C
core +1 more source
Frontiers in Pharmacology, 2022 Background: Vadadustat is a novel drug for treating anemia patients with chronic kidney disease (CKD), but its effect and safety remain uncertain. This study aimed to summarize the evidence for vadadustat in the treatment of CKD patients with anemia ...
Limei Xiong +8 more
doaj +1 more source